** Morningstar says it is upbeat on Australia's Telix Pharmaceuticals after co reported FY24 revenue ahead of its own and brokerage's forecasts
** "Telix is broadly tracking our expectations and we leave our constant-currency forecasts broadly unchanged," says brokerage
** Morningstar raises fair value estimate on stock by 6% to A$18, largely on stronger U.S. dollar
** Seven of eight analysts rate the stock "buy" or higher, one "hold"; their median PT is A$23.80 – LSEG data
** Stock has gained 1.5% YTD, as of last close
(Reporting by Rajasik Mukherjee in Bengaluru)
((Rajasik.Mukherjee@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。